Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma - PubMed (original) (raw)

Comparative Study

Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma

K S McCarty Jr et al. Cancer. 1980.

Abstract

Using a modification of the histologic grading system of the NSABP, we observed a trend towards higher levels of estrogen (E2R) and progesterone receptor (PR) content in well (grade I) and moderately (grade II) differentiated mammary carcinomas. This relationship between receptor content and histologic grade is enhanced by considering estrogen and progesterone receptor simultaneously. The rank correlation between the quantitative levels of E2R and PR was 0.74 among histologic grade I tumors and 0.64 among histologic grade II tumors. Among the grade III carcinomas, the majority of tumors displayed either a paucity of measurable receptor or a divergence between levels of estrogen versus progesterone receptor (r = 0.19). The use of ultrastructural evaluation of features of differentiation is discussed in the evaluation of grade III tumors and in the evaluation of specific histologic types of mammary carcinoma.

PubMed Disclaimer

Similar articles

• [Correlations between receptor state and various clinico-morphological parameters: evaluation of circa 2000 cases of breast tumors].
  Lampertico P, Stagni F. Lampertico P, et al. Pathologica. 1985 May-Jun;77(1049):281-97. Pathologica. 1985. PMID: 3008068 Italian. No abstract available.
• Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
  Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Hietanen T, Aine R, Taskinen PJ. Blanco G, et al. Anticancer Res. 1984 Nov-Dec;4(6):383-9. Anticancer Res. 1984. PMID: 6097159
• Correlation between histopathologic features and estrogen receptor status in primary breast cancer.
  Mantouvalos H, Makrygiannakis A, Metallinos C, Yianniou A, Gouskos A. Mantouvalos H, et al. Int J Gynaecol Obstet. 1984 Jun;22(3):177-9. doi: 10.1016/0020-7292(84)90002-x. Int J Gynaecol Obstet. 1984. PMID: 6148273
• Morphologic assay of steroid hormone receptors in human neoplasia.
  Pertschuk LP, Tobin EH, Brigati DJ, Gaetjens E. Pertschuk LP, et al. Pathol Annu. 1980;15(Pt 2):143-80. Pathol Annu. 1980. PMID: 6161331 Review. No abstract available.
• [Hormone receptors and precancerous lesions of the breast].
  Mignot L, Espie M, de Roquancourt A, Gorins A. Mignot L, et al. Pathol Biol (Paris). 1983 Nov;31(9):761-4. Pathol Biol (Paris). 1983. PMID: 6318180 Review. French.

Cited by

• Progesterone receptors and human breast cancer.
  Clark GM, McGuire WL. Clark GM, et al. Breast Cancer Res Treat. 1983;3(2):157-63. doi: 10.1007/BF01803558. Breast Cancer Res Treat. 1983. PMID: 6351950 Review.
• A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
  Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL. Xia W, et al. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. doi: 10.1073/pnas.0602468103. Epub 2006 May 8. Proc Natl Acad Sci U S A. 2006. PMID: 16682622 Free PMC article.
• Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.
  Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y. Toneff MJ, et al. Neoplasia. 2010 Sep;12(9):718-26. doi: 10.1593/neo.10516. Neoplasia. 2010. PMID: 20824048 Free PMC article.
• Measurement of oestrogen receptor mRNA levels in human breast tumours.
  Henry JA, Nicholson S, Farndon JR, Westley BR, May FE. Henry JA, et al. Br J Cancer. 1988 Nov;58(5):600-5. doi: 10.1038/bjc.1988.267. Br J Cancer. 1988. PMID: 2851309 Free PMC article.
• Cytochemistry of sex steroid receptors: a critique.
  McCarty KS Jr, Reintgen DS, Seigler HF, McCarty KS Sr. McCarty KS Jr, et al. Breast Cancer Res Treat. 1981;1(4):315-25. doi: 10.1007/BF01806747. Breast Cancer Res Treat. 1981. PMID: 6756511 No abstract available.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program